Stay updated on Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial page.

Latest updates to the Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedA new revision entry (v3.6.5) was added to the record history, indicating an update to the page's version history. The previous revision (v3.6.4) is superseded in the history.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThe Study Record History shows a new site revision tag (v3.6.4) replacing the previous v3.6.3, reflecting a backend or UI update rather than a change to the study content.SummaryDifference0.1%

- Check54 days agoChange DetectedA new revision entry v3.6.3 has been added to the study's record history, replacing the previous v3.6.2 entry. This reflects an update to the study record's versioning and documentation.SummaryDifference0.1%

- Check61 days agoChange DetectedA new revision entry, v3.6.2, was added to the Record History and the previous v3.6.0 entry was removed, indicating the study record was updated to reflect a newer version.SummaryDifference0.1%

- Check75 days agoChange DetectedThe study’s history now shows that recruitment has ended and adds a new revision (v3.6.0), while the older revision note (v3.5.5) was removed.SummaryDifference0.3%

- Check83 days agoChange DetectedOn 2026-06-03, results have been posted and the Outcome Measures (Results) section is now populated. The record shows a Study Status update and a new Revision: v3.5.5.SummaryDifference0.6%

Stay in the know with updates to Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial page.